Develops diagnostic tests for lung cancer and asthma.
Jun 2026Revenue $5.90M/yrExpenses $18.3M/yr
No trendCash runway ≈ 3 months from Jun 2026
Figures by year
When will bioAffinity Technologies be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $5.90M and expenses $18.3M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $6.16M | $16.7M | −$10.6M |
| Dec 2024 | $9.36M | $18.3M | −$8.95M |
| Dec 2023 | $2.53M | $10.5M | −$7.97M |
| Dec 2022 | $4.80K | $4.02M | −$4.01M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.